Literature DB >> 8527276

The acceptability of resin therapy to patients attending a hospital lipid clinic.

S A Iversen1, D Davidson, C Davidson.   

Abstract

Low dose cholestyramine ('Questran A') and colestipol ('Colestid Orange') were compared in a blinded two period crossover study of 55 patients attending a hospital lipid clinic. Colestipol was rated higher on a combined acceptability/palatability score. Both treatments reduced low density lipoprotein (LDL) cholesterol to a similar extent.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8527276      PMCID： PMC1365035          DOI： 10.1111/j.1365-2125.1995.tb04542.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  3 in total

1.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

2.  Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.

Authors:  D J Betteridge; P M Dodson; P N Durrington; E A Hughes; M F Laker; D P Nicholls; J A Rees; C A Seymour; G R Thompson; A F Winder
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

3.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245
  3 in total
  1 in total

1.  Applicability of dielectric measurements to the adsorption of beta blockers onto a pharmaceutical grade ion-exchange resin.

Authors:  L Marchal-Heussler; N Colling; E Benoit; P Maincent; J Bessiere
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.